Meihua International Medical T –


YANGZHOU, China, May 20, 2022 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (NASDAQ: MHUA), a reputable manufacturer and supplier of Class I, II and III disposable medical devices with operating subsidiaries in Chinaannounced today that the May 18, 2022it has received a notice from the Nasdaq Stock Market (“Nasdaq”) stating that, because the company has not yet filed its annual report on Form 20-F for the fiscal year ended December 31, 2021, the Company is not in compliance with the Nasdaq Continuing Listing Rules (specifically, Rule 5250(c)(1)). Under applicable Nasdaq rules, the Company now has 60 calendar days to submit a plan to restore compliance. If the Nasdaq accepts their plan, the Company may be granted an exception of up to 180 calendar days from the filing due date, or until November 14, 2022, to regain compliance.

In response to this notice, the Company intends to complete and file its Annual Report on Form 20-F for the year ended December 31, 2021 as soon as possible, and well in time to regain compliance with the applicable Listing Rules.

The notice has no immediate impact on the listing or trading of the Company’s securities on Nasdaq.

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies, a reputable manufacturer and supplier of Class I, II and III disposable medical devices with operating subsidiaries in China. The company manufactures and sells Class I disposable medical devices such as eye drop bottles, medicine bottles, anal bags, etc., Class II and III disposable medical devices such as ID tapes , gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressings, masks. , disposable infusion pumps, electronic pumps, puncture kits, etc. under their own brands and also distribute these disposable medical devices from other manufacturers. The company has received international “CE” certification and ISO 13485 system certification, and also registered with the FDA (registration number: 3006554788), for more than 20 products. The company has been serving hospitals, pharmacies, medical facilities and medical equipment companies for over 30 years with over 800 products for domestic sales, as well as 120 products for exports to over 30 countries worldwide. . Europe, North America, South America, Asia, Africa, and Oceania. For more information, please visit:

Forward-looking statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding future plans, objectives, goals, strategies, events or performance, as well as underlying assumptions and other statements other than statements of historical fact. Where the Company uses words such as “may”, “will”, “intend”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate” or similar expressions that do not relate solely to material, it makes forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from the Company’s expectations described in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s objectives and strategies; the future business development of the Company; financial condition and results of operations; requesting and accepting products and services; reputation and brand; the impact of competition and pricing; changes in technology; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or relating to any of the foregoing and other risks contained in the Company’s filings with the SEC. For these and other reasons, investors are cautioned not to place undue reliance on any forward-looking statements contained in this press release. Other factors are discussed in the Company’s filings with the SEC, which may be viewed at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances occurring after the date hereof.

For more information please contact:

Investor Relations
EverGreen Consulting Inc.
M/s. Janice WangManaging Partner
E-mail: [email protected]
Phone: +1 571-464-9470 (from the United States)
+86 13811768559 (from China)

View original content: – report-on-form-20-f-301552128.html

SOURCEMeihua International Medical Technologies Co., Ltd.

Source link


Comments are closed.